|
rs1051753269
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
|
30588029 |
2019 |
|
rs884225
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, rs884225 may be a biomarker for NSCLC susceptibility, and miR-103a-3p may be a potential therapeutic target in NSCLC.
|
30470824 |
2019 |
|
rs1032737355
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we present a case of a patient with non-small cell lung cancer (NSCLC) harboring 3 uncommon mutations of EGFR-R670W in exon 17 and H833V, and H835L in exon 21, as shown by next-generation sequencing of plasma cell-free DNA.
|
30127622 |
2018 |
|
rs149840192
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this case, Icotinib prevented completion of the signal transduction cascade of p.A289V mutant in NSCLC.
|
30572543 |
2018 |
|
rs397517096
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
|
29673089 |
2018 |
|
rs397517128
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Here, we present a case of a patient with non-small cell lung cancer (NSCLC) harboring 3 uncommon mutations of EGFR-R670W in exon 17 and H833V, and H835L in exon 21, as shown by next-generation sequencing of plasma cell-free DNA.
|
30127622 |
2018 |
|
rs9642391
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, our study provides evidence that rs9642391C>G in the intron of EGFR is associated with GBAS expression and survival outcomes of patients with surgically resected early-stage NSCLC.
|
29806744 |
2018 |
|
rs1050171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy.
|
27750395 |
2017 |
|
rs754426793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
|
28625641 |
2017 |
|
rs376822837
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Somatic mutations in MEK1 gene (substitutions K57N, Q56P, D67N) were described in <1 % of non-small cell lung cancer (NSCLC) and they were more commonly reported in adenocarcinoma patients with current or former smoking status.
|
26860843 |
2016 |
|
rs712829
|
|
|
0.010 |
GeneticVariation |
BEFREE |
EGFR rs712829 polymorphism and AKT1 rs1130214 could influence the response to EGFR-TKIs therapy in patients with advanced NSCLC.
|
26269114 |
2016 |
|
rs773454677
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Expression of the mutant KIT(D816G) receptor in ROS1-positive NSCLC cell lines led to constitutively activated KIT as measured by phosphorylation of the KIT receptor.
|
27068398 |
2016 |
|
rs909797662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Expression of the mutant KIT(D816G) receptor in ROS1-positive NSCLC cell lines led to constitutively activated KIT as measured by phosphorylation of the KIT receptor.
|
27068398 |
2016 |
|
rs1427028322
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We present a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
|
26237499 |
2015 |
|
rs778199483
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
|
25173530 |
2014 |
|
rs774487133
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS mutations were found in 18 (7.2%) patients (15 in adenocarcinoma, 2 in squamous cell carcinoma and one in NSCLC-not otherwise specified), including an uncommon substitution G13C.
|
24040454 |
2013 |
|
rs1171287261
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotypes for the intron 1 (CA)n repeat and R497K polymorphisms in the EGFR gene and the *2A (3801 T→C) and *2C (2455 A→G) polymorphisms in CYP1A1 gene were evaluated in 115 NSCLC patients by PCR-RFLP and DNA sequencing.
|
21616658 |
2011 |
|
rs6958497
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Stepwise COX regression analyses suggested that EGFR rs373506, rs759165 and rs6958497 may be independent candidate biomarkers to predict NSCLC survival in this population.
|
20400478 |
2010 |
|
rs759165
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Stepwise COX regression analyses suggested that EGFR rs373506, rs759165 and rs6958497 may be independent candidate biomarkers to predict NSCLC survival in this population.
|
20400478 |
2010 |
|
rs2293347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
During sequencing of EGFR C-terminal domain in NSCLC, 194 EGFR polymorphism (C2982T) cases were identified at exon 25.
|
18478265 |
2008 |
|
rs374873413
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
|
31301016 |
2019 |
|
rs374873413
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
|
29571986 |
2018 |
|
rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Genotypes for the intron 1 (CA)n repeat and R497K polymorphisms in the EGFR gene and the *2A (3801 T→C) and *2C (2455 A→G) polymorphisms in CYP1A1 gene were evaluated in 115 NSCLC patients by PCR-RFLP and DNA sequencing.
|
21616658 |
2011 |
|
rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
AKT1-SNP4 A/A genotype seems to be a candidate biomarker of primary resistance, whereas EGFR -191C/A, -216G/T, and R497K polymorphisms are associated with diarrhea when using gefitinib in NSCLC patients, thus offering potential new tools for treatment optimization.
|
20159991 |
2010 |
|
rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Four tag SNPs, one CA simple sequence repeat (CA-SSR) in intron 1, one coding region SNP (R521K), and SNPs identified by resequencing in the tyrosine kinase domain of EGFR were selected to analyze their association with therapeutic outcome and survival in 84 advanced NSCLC patients treated with Gefitinib.
|
19201048 |
2009 |